Corium Entered into Exclusive Collaboration and License Agreement with Lotus Pharmaceutical for Adlarity to Treat Alzheimer's Disease
Shots:
- Corium will receive an up front & is eligible to receive regulatory and performance-based milestones based on net sales of the product
- Lotus to get an exclusive right to commercialize Adlarity in the applicable territory and will lead the regulatory approval process in the territory incl. Taiwan, South Korea, Hong Kong, Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam while Corium is responsible for supplying finished product to Lotus
- Adlarity was approved in the US as the first and only once-weekly patch for mild, mod., and sev. dementia of the Alzheimer’s type. The regulatory approval filing in some Asian markets is expected in 2023
Ref: Businesswire | Image: Corium
Related News:- Corium’s Adlarity (donepezil transdermal system) Receives the US FDA’s Approval for the Treatment of Alzheimer Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
